Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study-Reference-Cited by-同舟云学术

Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study

Published:2019-01-08 Issue:1 Volume:3 Page:
ISSN:2520-1026
Container-title:BMC Rheumatology
language:en
Short-container-title:BMC Rheumatol

Author:

Staples Margaret P.,March Lyn,Hill Catherine,Lassere Marissa,Buchbinder Rachelle^ORCID

Funder

Commonwealth Government of Australia National Health & Medical Research Council

Monash University

Australian Rheumatology Association

Abbott Australia

Pfizer Australia

Jansssen Australia

Sanofi Aventis

Amgen

Wyeth

Schering-Plough

Roche

NHMRC Senior Principal Research Fellowship

Publisher

Springer Science and Business Media LLC

Subject

Rheumatology

Link

http://link.springer.com/content/pdf/10.1186/s41927-018-0050-7.pdf

Reference39 articles.

1. Lebrec H, Ponce R, Preston B, Iles J, Born T, Hooper M. Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk. Curr Med Res Op. 2015;31:557–74.

2. Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70:1895–904.

3. Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76:1101–36.

4. Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskel Dis. 2008;9:52.

5. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68:1136–45.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A narrative review of the comparative safety of disease-modifying anti-rheumatic drugs used for the treatment of rheumatoid arthritis;Expert Opinion on Drug Safety;2024-05-23

2. Recomendaciones SER sobre la gestión de riesgo del tratamiento con FAME biológicos o sintéticos dirigidos en pacientes con artritis reumatoide;Reumatología Clínica;2023-12

3. Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis;Reumatología Clínica (English Edition);2023-12

4. Malignancies and rheumatoid arthritis, csDMARDs, biological DMARDs, and JAK inhibitors: challenge and outlook;Expert Review of Clinical Immunology;2023-08-14

5. Biologic therapy is associated with malignancies among Israeli patients with rheumatoid arthritis: A population‐based study;International Journal of Rheumatic Diseases;2023-06-03